Evidence map›Paper›PMID 32617404›Full record

ArticleACS biomaterials science & engineering2020

Sulfation modulates the targeting properties of hyaluronic acid to P-selectin and CD44.

Deep S Bhattacharya, Denis Svechkarev, Aishwarya Bapat, Prathamesh Patil, Michael A Hollingsworth, Aaron M Mohs

Open access · greenAbstract read
In one paragraph

Article in ACS biomaterials science & engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Glycosaminoglycans as Polyelectrolytes: Charge, Interactions, and Applications.Chembiochem : a European journal of chemical biology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Fluorescent Graphitic Carbon Nitride (g-CPharmaceuticals (Basel, Switzerland) · 2024
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Platelets for cancer treatment and drug delivery.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Deep S BhattacharyaDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Denis SvechkarevDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Aishwarya BapatDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Prathamesh PatilEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Michael A HollingsworthEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Aaron M MohsDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States.
University of Nebraska Medical Center · US

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
Research Pilot Project ProgramP30GM106397 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JOHNSON, KEITH R · 2013 to 2017
$4.9M
Hyaluronic Acid Based Nanoparticles for Targeted Image-Guided Tumor SurgeryR01EB019449 · NIBIB · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MOHS, AARON M. · 2014 to 2017
$1.3M
NCI NIH HHS P30 CA036727NIBIB NIH HHS R01 EB019449NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P30 GM106397
6 · The paper itself

Abstract

Many targeting strategies can be employed to direct nanoparticles to tumors for imaging and therapy. However, tumors display a dynamic, heterogeneous microenvironment that undergoes spatiotemporal changes, including the expression of targetable cell-surface biomarkers. Here, we develop a nanoparticle system to effectively target two receptors overexpressed in the microenvironment of aggressive tumors. Hyaluronic acid (HA) was regioselectivity modified using a multi-step synthetic approach to alter binding specificities for CD44 and P-selectin to tumor cell interaction. The dual-targeting strategy utilizes sulfate modifications on HA that targets P-selectin, in addition to native targeting of CD44, which exploits spatiotemporal alterations in the expression patterns of these two receptors in cancer sites. Using biophysical characterization and

Indexed as

Hyaluronic AcidNanoparticlesCell Line, TumorP-SelectinHyaluronic AcidP-SelectinCD44dual targethyaluronic acidnear infraredP-selectin

Identifiers

PMID32617404
PMCPMC7331950
OpenAlexW3021002470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.